Mycenax Biotech (4726) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 永昕

Mycenax Biotech (4726) reported revenue of NT$98 million for Oct 2026, +41.0% year on year and -15.8% from the previous month. Revenue for Jan–Oct 2026 was NT$806.1 million (+53.5% year on year).

Year-on-year revenue growth: 4 months in a row. →

In Oct 2026, it ranked No. 75 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$35.3 million24/10Nov 2024 NT$109.1 millionDec 2024 NT$49.7 millionJan 2025 NT$45.2 millionFeb 2025 NT$23.5 million25/02Mar 2025 NT$52.9 millionApr 2025 NT$26.6 millionMay 2025 NT$70.5 millionJun 2025 NT$105.4 million25/06Jul 2025 NT$62 millionAug 2025 NT$45.7 millionSep 2025 NT$23.6 millionOct 2025 NT$69.5 million25/10Nov 2025 NT$87.8 millionDec 2025 NT$127.3 millionJan 2026 NT$45.7 millionFeb 2026 NT$56.6 million26/02Mar 2026 NT$94.6 millionApr 2026 NT$106.7 millionMay 2026 NT$42.5 millionJun 2026 NT$53.8 million26/06Jul 2026 NT$86 millionAug 2026 NT$105.9 millionSep 2026 NT$116.4 millionOct 2026 NT$98 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$98 million+41.0%-15.8%
Sep 2026NT$116.4 million+393.3%+9.9%
Aug 2026NT$105.9 million+131.4%+23.1%
Jul 2026NT$86 million+38.6%+59.6%
Jun 2026NT$53.8 million-48.9%+26.7%
May 2026NT$42.5 million-39.7%-60.2%
Apr 2026NT$106.7 million+301.0%+12.9%
Mar 2026NT$94.6 million+78.6%+67.1%
Feb 2026NT$56.6 million+140.4%+23.9%
Jan 2026NT$45.7 million+0.9%-64.1%
Dec 2025NT$127.3 million+156.4%+45.0%
Nov 2025NT$87.8 million-19.5%+26.3%
Oct 2025NT$69.5 million+97.1%+194.6%
Sep 2025NT$23.6 million-60.6%-48.4%
Aug 2025NT$45.7 million-33.8%-26.3%
Jul 2025NT$62 million-22.5%-41.1%
Jun 2025NT$105.4 million+20.3%+49.4%
May 2025NT$70.5 million+18.4%+165.0%
Apr 2025NT$26.6 million-50.1%-49.7%
Mar 2025NT$52.9 million+28.1%+125.0%
Feb 2025NT$23.5 million-0.3%-48.0%
Jan 2025NT$45.2 million+196.5%-8.9%
Dec 2024NT$49.7 million-34.2%-54.5%
Nov 2024NT$109.1 million+150.6%+209.3%
Oct 2024NT$35.3 million-44.8%-41.2%

Jan–Oct 2026 cumulative: NT$806.1 million (+53.5% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Mycenax Biotech vs PEC / Mycenax Biotech vs Lotus Pharm / Mycenax Biotech vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

本公司以提供CDMO技術服務為主,收入係以滿足履約義務時認列,本月累計完成履約義務較去年累計增加。

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16